"Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System" ed. by Diana E. Pankevich, et al.
"Glutamate-Related Biomarkers in Drug Development for Disorders of the Nervous System" ed. by Diana E. Pankevich, Miriam Davis, and Bruce M. Altevogt
Workshop Summary. Forum on Neuroscience and Nervous System Disorders; Institute of Medicine
NAS Press | 2011 | ISBN: 0309212219 9780309212212 | 75 pages | PDF | 2 MB
Workshop Summary. Forum on Neuroscience and Nervous System Disorders; Institute of Medicine
NAS Press | 2011 | ISBN: 0309212219 9780309212212 | 75 pages | PDF | 2 MB
Problems with how the neurotransmitter glutamate functions in the brain have been linked to a wide variety of disorders, including schizophrenia, Alzheimer's, substance abuse, and traumatic brain injury. Efforts to understand, treat, and prevent glutamate-related disorders can be aided by the identification of valid biomarkers.
The IOM's Forum on Neuroscience and Nervous System Disorders held a workshop June 21-22, 2010, to explore ways to accelerate the development, validation, and implementation of such biomarkers.
Contents
1 INTRODUCTION
Glutamate Biomarker
Workshop Goals
2 OVERVIEW OF THE GLUTAMATERGIC SYSTEM
Glutamate Receptors
Glutamate Transporters
3 GLUTAMATE BIOMARKERS
Biomarkers of Engagement and Efficacy
Physiological Biomarkers
Cognitive Biomarkers
Imaging Biomarkers
4 TREATMENT IMPLICATIONS OF BIOMARKERS
Target Developments
Patient Stratification
Side-Effect Reduction
5 CHALLENGES AND OPPORTUNITIES
Challenges
Opportunities
Summary
APPENDIXES
A References
B Registered Attendees
C Agenda
with TOC BookMarkLinks